Sorafenib dose escalation in the treatment of advanced hepatocellular carcinoma

Oncology
Jeong Eun KimYoon-Koo Kang

Abstract

Although sorafenib has shown survival benefits in patients with hepatocellular carcinoma (HCC), many patients require discontinuation or dose reduction due to adverse events (AEs). We applied a dose escalation scheme to increase patient compliance and avoid AEs. Of 267 HCC patients treated with first-line sorafenib, 25 at increased risk of AEs, including those with advanced liver cirrhosis, a history of liver transplantation, or cytopenia, received the dose escalation scheme. They started on a reduced dose of sorafenib which increased to the standard dosage according to tolerance in each patient. We analyzed the efficacy and safety of the dose escalation scheme. Patients with risk factors showed a lower disease control rate, shorter survival, and more frequently grade 3/4 AEs. Among patients presenting risk factors, the dose scheme did not affect the efficacy of sorafenib or survival, but reduced the incidence of grade 3/4 AEs. Rates of sorafenib discontinuation and dose reduction related to AEs were also lower in the dose escalation group. Dose escalation to the standard dose of sorafenib was achieved in 16 of the 25 patients in the dose escalation group (64.0%). After 2 weeks, the dose intensity of sorafenib did not differ be...Continue Reading

References

Dec 12, 2003·Lancet·Josep M LlovetJordi Bruix
Dec 23, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Dirk StrumbergSiegfried Seeber
Aug 25, 2005·Journal of Hepatology·Pietro MajnoUNKNOWN Geneva Liver Cancer Study
Oct 27, 2005·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Jordi BruixUNKNOWN Practice Guidelines Committee, American Association for the Study of Liver Diseases
Jul 25, 2008·The New England Journal of Medicine·Josep M LlovetUNKNOWN SHARP Investigators Study Group
May 25, 2010·Japanese Journal of Clinical Oncology·Dok Hyun YoonYoon-Koo Kang

❮ Previous
Next ❯

Citations

Jan 15, 2016·Colloids and Surfaces. B, Biointerfaces·Wang YanhuaShengmin Zhang
May 8, 2014·Hepatology Research : the Official Journal of the Japan Society of Hepatology·Manabu MorimotoKatsuaki Tanaka
Jan 12, 2013·Liver International : Official Journal of the International Association for the Study of the Liver·Katsutoshi SugimotoYasuharu Imai
Feb 23, 2013·Oncology·Liliana MontellaSalvatore Del Prete
Sep 6, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Kim A ReissDavid E Kaplan
Mar 17, 2017·Targeted Oncology·Gillian M Keating
Apr 1, 2014·Hepatic Oncology·Marcus Alexander Wörns, Peter Robert Galle
Nov 20, 2020·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Robert J Cersosimo

❮ Previous
Next ❯

Related Concepts

Related Feeds

Carcinoma, Hepatocellular

Hepatocellular Carcinoma is a malignant cancer in liver epithelial cells. Discover the latest research on Hepatocellular Carcinoma here.